Venus Remedies expands presence in Vietnam with marketing nods for Methotrexate, Cefuroxime, Irinotecan
Venus Remedies Limited has received new marketing authorizations for Methotrexate, Cefuroxime, and Irinotecan in Vietnam.
These regulatory approvals bolster the company’s expanding export footprint in South Asia’s fast-growing pharmaceutical sector, taking its portfolio to 29 active product approvals in Vietnam alone.
These latest approvals add to the company’s growing list of more than 374 marketing authorizations in the ASEAN region.
Saransh Chaudhary, President, Global Critical Care, Venus Remedies Limited, and CEO, Venus Medicine Research Centre, remarked, “This expansion is aligned with our mission to democratize access to advanced critical care therapies across emerging markets. Southeast Asia remains a strategic geography for Venus, and we are committed to deepening our presence here through sustained portfolio diversification and long-term partnerships.”
Vietnam is India’s 15th largest trading partner and among its top four pharmaceutical export destinations in Southeast Asia. Over the past five years, bilateral trade in pharmaceuticals has grown steadily, driven by the rising demand for complex generics and affordable oncology and antimicrobial therapies. The broader ASEAN pharmaceutical market is projected to reach USD 63.5 billion by 2029, underscoring the region’s importance in India’s global trade strategy.
Aditi K. Chaudhary, President, International Business, Venus Remedies Limited, added, “With these approvals, we are deepening our commitment to healthcare providers and patients in Vietnam. Each regulatory milestone helps us remain focused on building resilient supply chains and forging meaningful collaborations that elevate care standards across borders.”
Panchkula-based Venus Remedies Ltd has a commercial presence in 90+ countries with a portfolio of 75 products spread over Europe, Australia, Africa, Asia-Pacific, Commonwealth States, the Middle East, Latin America and the Caribbean region, the company has nine globally benchmarked facilities in Panchkula, Baddi and Werne (Germany), apart from 11 overseas marketing offices. The company holds the GMP approvals from European- GMP (INFARMED), PIC/S (Malaysia & Ukraine), SAHPRA, UNICEF, TGA, INVIMA & WHO-GMP, alongside key ISO certifications for quality, environmental, and occupational health and safety management.
Next Story